出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年10月
Preimplantation Genetic Testing Market – Global Forecast to 2028
着床前遺伝子検査市場 : 手順 (診断、スクリーニング)、技術 (NGS、PCR、FISH、CGH、SNP)、製品 (消耗品、器具)、用途 (異数体、HLA タイピング)、周期の種類、エンド ユーザー、地域別 – 2028年までの世界予測
Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region – Global Forecast to 2028
| ページ数 | 238 |
| 図表数 | 226 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global preimplantation genetic testing market is projected to reach USD 1.2 Billion by 2028 from USD 0.7 Billion in 2023, at a CAGR of 11.4% during the forecast period. The growth of this market is majorly driven by the rising number of fertility clinics and IVF centers and a boost in public-private investments in the development of novel diagnostic techniques. However, unfavorable government regulations and healthcare reforms for IVF procedures restrain the growth of the preimplantation genetic testing market.
“The next generation sequencing segment accounted for the highest market share in the preimplantation genetic testing market, by technology, during the forecast period.”
Based on the type segment, the preimplantation genetic testing market is categorized into PCR, NGS, FISH, CGH, and SNP. The ability to sequence DNA has opened up abundant application avenues for NGS technologies in infertility treatment. NGS offers various advantages such as reduced cost, better ability to detect an embryo with differing results (mosaicism), and enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments.
“Aneuploidy application segment accounted for the highest CAGR during the forecast period.”
Based on application, the preimplantation genetic testing market is segmented into aneuploidy, structural chromosomal abnormalities, single gene disorders, X-linked disorders, HLA typing, and gender identification. The use of preimplantation genetic screening for aneuploidy detection increases the chance of an embryo implantation, decreases the miscarriage rate, and reduces the chance of having a child with a chromosome abnormality. These advantages are driving the demand for preimplantation genetic testing for detecting aneuploidy.
“The Asia Pacific segment accounted for the highest growth rate in the preimplantation genetic testing systems market, by region, during the forecast period.”
Based on the region, the global preimplantation genetic testing market is categorized into North America, Europe, Asia Pacific, and Rest of the World. Asia Pacific is expected to witness a high growth rate during the forecast period. As a result of the rapid economic growth in the emerging countries in Asia-Pacific, the disposable income levels in the region’s countries such as China and India have witnessed a notable increase in the last decade which holds massive potential for the Asia Pacific preimplantation genetic testing market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (50%), Tier 2 (33%), and Tier 3 (17%)
• By Designation: C-level (17%), Director-level (50%), and Others (33%)
• By Region: North America (34%), Europe (35%), Asia- Pacific (26%), and Rest of the World (5%)
Prominent companies include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), The Cooper Companies, Inc. (US), Abbott (US), Takara Bio Inc. (Japan), Qiagen (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies Plc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), Shiva Scientific Company (India), Nanjing Superyears Gene Technology Co. Ltd. (China), Medicover Genetics (Germany), Medgenome (India), Fulgent Genetics (US), Invicta Genetics (Poland), Genea Limited (Australia), Scigene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co. Ltd. (China), Genemind Biosciences Co. Ltd. (China), Berry Genomics (China), and Bangkok Genomics Innovation (Thailand).
Research Coverage
This research report categorizes the preimplantation genetic testing market by procedure type (preimplantation genetic screening, and preimplantation genetic diagnosis), by technology (next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, single-nucleotide polymorphism), by product and service (reagents and consumables, instruments, and software and services), by application (aneuploidy, structural chromosomal abnormalities, single gene disorders, x-linked disorders, HLA typing, and gender identification), by type of cycle (fresh non-donor, frozen non-donor, fresh donor, and frozen donor), by end user (fertility clinics, hospitals, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the preimplantation genetic testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the preimplantation genetic testing market. Competitive analysis of upcoming startups in the preimplantation genetic testing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall preimplantation genetic testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (declining rate of fertility worldwide, the rise of fertility tourism in emerging economies, increasing number of fertility clinics and IVF centers, increasing public-private investments in development of novel diagnostic techniques, high risk of chromosomal abnormalities with advancing maternal age), restraints (high procedural cost in preimplantation genetic testing, and unfavorable government regulation and healthcare reforms for IVF procedures), opportunities (improving healthcare infrastructure and rising medical tourism in emerging economies, and Use of fertility treatment options by single parents and same-sex couples), and challenges (socio-ethical concerns surrounding preimplantation genetic testing, and procedural limitation of preimplantation genetic testing with advancing age) influencing the growth of the preimplantation genetic testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the preimplantation genetic testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the preimplantation genetic testing market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the preimplantation genetic testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US), among others in the preimplantation genetic testing market strategies.
Table of Contents
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 INCLUSIONS AND EXCLUSIONS 31
1.4 STUDY SCOPE 32
1.4.1 MARKETS CONSIDERED 32
FIGURE 1 PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION 32
1.4.2 YEARS CONSIDERED 33
1.4.3 CURRENCY CONSIDERED 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 2 RESEARCH DESIGN: PREIMPLANTATION GENETIC TESTING MARKET 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
FIGURE 3 PRIMARY SOURCES 38
2.1.2.1 Key industry insights 39
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primary interviews 40
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 41
2.2.1.1 Approach 1: Company revenue estimation approach 41
FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH 41
2.2.1.2 Approach 2: Presentations of companies and primary interviews 41
2.2.1.3 Approach 4: Usage-based market estimation 42
FIGURE 6 MARKET SIZE ESTIMATION, BY PRODUCT UTILIZATION METHODOLOGY 42
2.2.1.4 Growth forecast 43
2.2.1.5 CAGR projections 43
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
2.2.2 TOP-DOWN APPROACH 43
FIGURE 8 TOP-DOWN APPROACH 44
2.3 MARKET ESTIMATION AND DATA TRIANGULATION 45
FIGURE 9 DATA TRIANGULATION METHODOLOGY 45
2.4 STUDY ASSUMPTIONS 46
2.5 RESEARCH LIMITATIONS 46
2.6 RISK ASSESSMENT 47
TABLE 1 RISK ASSESSMENT: PREIMPLANTATION GENETIC TESTING MARKET 47
2.7 RECESSION IMPACT ANALYSIS: PREIMPLANTATION GENETIC TESTING MARKET 47
3 EXECUTIVE SUMMARY 48
FIGURE 10 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 11 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 14 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 15 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
FIGURE 16 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 54
4 PREMIUM INSIGHTS 55
4.1 PREIMPLANTATION GENETIC TESTING MARKET OVERVIEW 55
FIGURE 17 RISING MATERNAL AGE AND DECLINING FERTILITY RATES TO DRIVE MARKET 55
4.2 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION (2023–2028) 56
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 56
4.3 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND COUNTRY (2021) 57
FIGURE 19 US AND REAGENTS AND CONSUMABLES SEGMENT COMMANDED LARGEST MARKET SHARE IN 2022 57
4.4 PREIMPLANTATION GENETIC TESTING MARKET: REGIONAL GROWTH OPPORTUNITIES 58
FIGURE 20 ASIA PACIFIC COUNTRIES TO GROW AT HIGHEST RATE DURING STUDY PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: PREIMPLANTATION GENETIC TESTING MARKET 59
5.2.1 DRIVERS 60
5.2.1.1 Decline in fertility rates 60
TABLE 2 FERTILITY RATE, TOTAL (BIRTHS PER WOMAN), BY COUNTRY 60
5.2.1.2 Rise of fertility tourism in emerging economies 60
5.2.1.3 Increasing number of fertility clinics and IVF centers 61
5.2.1.4 Increasing public-private investments to develop novel diagnostic techniques 61
5.2.1.5 High risk of chromosomal abnormalities with advancing maternal age 62
TABLE 3 GLOBAL INCIDENCE RATE OF TRISOMY 62
5.2.2 RESTRAINTS 62
5.2.2.1 High procedural cost 62
5.2.2.2 Unfavorable government regulations and healthcare reforms for IVF procedures 63
5.2.3 OPPORTUNITIES 63
5.2.3.1 Improving healthcare infrastructure and rising medical tourism in emerging economies 63
5.2.3.2 Use of fertility treatments by single parents and same-sex couples 64
5.2.4 CHALLENGES 65
5.2.4.1 Socio-ethical concerns surrounding preimplantation genetic testing 65
5.2.4.2 Age-related procedural challenges 65
5.3 PRICING ANALYSIS 66
TABLE 4 INDICATIVE PRICING OF PREIMPLANTATION GENETIC TESTING PRODUCTS 66
TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS 66
5.4 VALUE CHAIN ANALYSIS 67
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 67
5.5 SUPPLY CHAIN ANALYSIS 68
FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY OF PROMINENT COMPANIES 68
5.6 PORTER’S FIVE FORCES ANALYSIS 69
5.6.1 THREAT OF NEW ENTRANTS 69
5.6.2 THREAT OF SUBSTITUTES 69
5.6.3 BARGAINING POWER OF SUPPLIERS 69
5.6.4 BARGAINING POWER OF BUYERS 70
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.7 ECOSYSTEM MARKET MAP 70
FIGURE 24 ECOSYSTEM MARKET MAP: PREIMPLANTATION GENETIC TESTING MARKET 70
TABLE 6 ROLE IN ECOSYSTEM: PREIMPLANTATION GENETIC TESTING MARKET 71
FIGURE 25 KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 72
5.8 REGULATORY ANALYSIS 72
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING PREIMPLANTATION GENETIC TESTING MARKET 72
5.8.1 NORTH AMERICA 73
5.8.1.1 US 73
5.8.1.2 Canada 73
5.8.2 EUROPE 74
5.8.2.1 UK 74
5.8.2.2 France 74
5.8.3 ASIA PACIFIC 74
5.8.3.1 Japan 74
5.8.3.2 India 74
5.9 PATENT ANALYSIS 75
5.9.1 PATENT TRENDS FOR PREIMPLANTATION GENETIC TESTING 75
FIGURE 26 PATENT TRENDS FOR PREIMPLANTATION GENETIC TESTING, JANUARY 2013–AUGUST 2023 75
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 76
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PREIMPLANTATION GENETIC TESTING PATENTS, JANUARY 2013–AUGUST 2023 76
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.10.1 REVENUE SHIFT FOR PREIMPLANTATION GENETIC TESTING PRODUCTS 77
FIGURE 28 REVENUE SHIFT FOR PREIMPLANTATION GENETIC TESTING PRODUCTS 77
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 78
TABLE 8 DETAILED LIST OF CONFERENCES AND EVENTS (JANUARY 2023–DECEMBER 2024) 78
5.12 TECHNOLOGY ANALYSIS 79
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 80
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 80
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PREIMPLANTATION GENETIC TESTING PRODUCTS 80
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PREIMPLANTATION GENETIC TESTING PRODUCTS (%) 80
5.13.2 BUYING CRITERIA 81
FIGURE 30 KEY BUYING CRITERIA FOR END USERS OF PREIMPLANTATION GENETIC TESTING MARKET 81
TABLE 10 KEY BUYING CRITERIA FOR END USERS OF PREIMPLANTATION GENETIC TESTING PRODUCTS 81
5.14 TRADE ANALYSIS 82
TABLE 11 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION) 82
TABLE 12 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION) 82
6 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE 83
6.1 INTRODUCTION 84
TABLE 13 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 84
6.2 PREIMPLANTATION GENETIC SCREENING 84
6.2.1 INCREASING MATERNAL AGE TO DRIVE MARKET 84
TABLE 14 PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC SCREENING, BY REGION, 2021–2028 (USD MILLION) 85
6.3 PREIMPLANTATION GENETIC DIAGNOSIS 85
6.3.1 RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO DRIVE MARKET 85
TABLE 15 PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2021–2028 (USD MILLION) 86
7 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY 87
7.1 INTRODUCTION 88
TABLE 16 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 88
7.2 NEXT-GENERATION SEQUENCING 88
7.2.1 IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO DRIVE MARKET 88
TABLE 17 PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 89
7.3 POLYMERASE CHAIN REACTION 89
7.3.1 INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO DRIVE MARKET 89
TABLE 18 PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION) 90
7.4 FLUORESCENCE IN SITU HYBRIDIZATION 90
7.4.1 ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO DRIVE MARKET 90
TABLE 19 PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 91
7.5 COMPARATIVE GENOMIC HYBRIDIZATION 91
7.5.1 LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 91
TABLE 20 PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 92
7.6 SINGLE-NUCLEOTIDE POLYMORPHISM 92
7.6.1 TIME-CONSUMING, EXPENSIVE, AND LABOR-INTENSIVE METHOD TO LIMIT MARKET 92
TABLE 21 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2021–2028 (USD MILLION) 93
8 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE 94
8.1 INTRODUCTION 95
TABLE 22 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 95
8.2 REAGENTS AND CONSUMABLES 95
8.2.1 REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE PREIMPLANTATION GENETIC TESTING MARKET 95
TABLE 23 PREIMPLANTATION GENETIC TESTING MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 96
8.3 INSTRUMENTS 96
8.3.1 ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO DRIVE MARKET 96
TABLE 24 PREIMPLANTATION GENETIC TESTING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 97
8.4 SOFTWARE AND SERVICES 97
8.4.1 RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET 97
TABLE 25 PREIMPLANTATION GENETIC TESTING MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2021–2028 (USD MILLION) 98
9 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION 99
9.1 INTRODUCTION 100
TABLE 26 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
9.2 ANEUPLOIDY 100
9.2.1 ANEUPLOIDY SEGMENT TO COMMAND LARGEST MARKET SHARE 100
TABLE 27 PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2021–2028 (USD MILLION) 101
9.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES 102
TABLE 28 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 29 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 102
9.3.1 TRANSLOCATIONS 103
9.3.1.1 Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment 103
TABLE 30 TRANSLOCATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 103
9.3.2 DELETIONS 104
9.3.2.1 Advancements in genetic testing to drive segment 104
TABLE 31 DELETIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
9.3.3 DUPLICATIONS 104
9.3.3.1 Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment 104
TABLE 32 DUPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
9.3.4 INVERSIONS 105
9.3.4.1 Risk of unexplained male‐factor infertility and multiple miscarriages to limit segment 105
TABLE 33 INVERSIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
9.4 SINGLE GENE DISORDERS 106
9.4.1 INCREASING AWARENESS ABOUT GENETIC TESTING TO DRIVE MARKET 106
TABLE 34 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY REGION, 2021–2028 (USD MILLION) 107
9.5 X-LINKED DISORDERS 107
9.5.1 MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO DRIVE MARKET 107
TABLE 35 PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY REGION, 2021–2028 (USD MILLION) 108
9.6 HLA TYPING 108
9.6.1 RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET 108
TABLE 36 PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION) 109
9.7 GENDER IDENTIFICATION 109
9.7.1 INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET 109
TABLE 37 PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY REGION, 2021–2028 (USD MILLION) 110
10 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE 111
10.1 INTRODUCTION 112
TABLE 38 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 112
10.2 FRESH NON-DONOR 112
10.2.1 HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET 112
TABLE 39 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONORS, BY REGION, 2021–2028 (USD MILLION) 113
10.3 FROZEN NON-DONOR 113
10.3.1 LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING TO DRIVE MARKET 113
TABLE 40 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY REGION, 2021–2028 (USD MILLION) 114
10.4 FROZEN DONOR 114
10.4.1 BETTER AFFORDABILITY, HIGHER AVAILABILITY, AND EASIER IMPLANTATION TO DRIVE MARKET 114
TABLE 41 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2021–2028 (USD MILLION) 115
10.5 FRESH DONOR 115
10.5.1 REAL-TIME GENETIC TESTING RESULTS AND EASY EMBRYO TRANSFER TO DRIVE MARKET 115
TABLE 42 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2021–2028 (USD MILLION) 116
11 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER 117
11.1 INTRODUCTION 118
TABLE 43 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 118
11.2 FERTILITY CLINICS 118
11.2.1 HIGH SUCCESS RATE OF TREATMENT TO DRIVE MARKET 118
TABLE 44 PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY REGION, 2021–2028 (USD MILLION) 119
11.3 HOSPITALS 119
11.3.1 RISING NUMBER OF HOSPITALS FOR ART PROCEDURES TO DRIVE MARKET 119
TABLE 45 PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 120
11.4 DIAGNOSTIC LABORATORIES 120
11.4.1 IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO DRIVE MARKET 120
TABLE 46 PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 121
11.5 OTHER END USERS 121
TABLE 47 PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 122
12 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION 123
12.1 INTRODUCTION 124
TABLE 48 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 124
12.2 NORTH AMERICA 125
12.2.1 NORTH AMERICA: RECESSION IMPACT 125
FIGURE 31 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 126
TABLE 49 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 50 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 127
TABLE 51 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 52 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 128
TABLE 53 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 54 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 55 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 130
TABLE 56 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
12.2.2 US 131
12.2.2.1 US to dominate North American preimplantation genetic testing market during forecast period 131
TABLE 57 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 132
TABLE 58 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
TABLE 59 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 133
TABLE 60 US: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 61 US: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 62 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 134
TABLE 63 US: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 135
12.2.3 CANADA 135
12.2.3.1 Increasing government and non-government funding for curbing rising infertility rates to drive market 135
TABLE 64 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 136
TABLE 65 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 66 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 137
TABLE 67 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 68 CANADA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 69 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 138
TABLE 70 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 139
12.3 EUROPE 139
12.3.1 EUROPE: RECESSION IMPACT 139
TABLE 71 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 72 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 140
TABLE 73 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
TABLE 74 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 141
TABLE 75 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 76 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 77 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 143
TABLE 78 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 143
12.3.2 GERMANY 144
12.3.2.1 Low fertility rate and low cost of infertility treatment to drive market 144
TABLE 79 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 144
TABLE 80 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 145
TABLE 81 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 145
TABLE 82 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 83 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 84 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 147
TABLE 85 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 147
12.3.3 FRANCE 148
12.3.3.1 Rising government funding for genomics research and increasing median age for first-time pregnancies to drive market 148
TABLE 86 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 148
TABLE 87 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 88 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 149
TABLE 89 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 90 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 91 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 151
TABLE 92 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
12.3.4 UK 152
12.3.4.1 Increasing IVF cycles and growing genetic abnormalities to drive market 152
TABLE 93 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 152
TABLE 94 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 153
TABLE 95 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 153
TABLE 96 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 97 UK: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 98 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 155
TABLE 99 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 155
12.3.5 ITALY 156
12.3.5.1 Technological advancements in fertility treatment and decline in fertility rates among women to drive market 156
TABLE 100 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 156
TABLE 101 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 102 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 157
TABLE 103 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158
TABLE 104 ITALY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 105 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 159
TABLE 106 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 159
12.3.6 SPAIN 160
12.3.6.1 Low cost of fertility treatment to drive market 160
TABLE 107 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 160
TABLE 108 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 161
TABLE 109 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 161
TABLE 110 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 111 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 112 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 163
TABLE 113 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 163
12.3.7 REST OF EUROPE 163
TABLE 114 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 164
TABLE 115 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 164
TABLE 116 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 165
TABLE 117 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 118 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 119 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 166
TABLE 120 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 167
12.4 ASIA PACIFIC 167
12.4.1 ASIA PACIFIC: RECESSION IMPACT 168
FIGURE 32 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT 169
TABLE 121 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 122 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 170
TABLE 123 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 171
TABLE 124 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 171
TABLE 125 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
TABLE 126 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 127 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 173
TABLE 128 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 173
12.4.2 CHINA 174
12.4.2.1 Decreasing fertility rates and abolishment of one-child policy to drive market 174
TABLE 129 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 174
TABLE 130 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175
TABLE 131 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 175
TABLE 132 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 133 CHINA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 134 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 177
TABLE 135 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 177
12.4.3 JAPAN 178
12.4.3.1 Rising adoption of IVF among infertile couples to drive market 178
TABLE 136 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 178
TABLE 137 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 179
TABLE 138 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 179
TABLE 139 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 180
TABLE 140 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 141 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 181
TABLE 142 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 181
12.4.4 INDIA 182
12.4.4.1 Rising medical tourism and increasing fertility clinics to drive market 182
TABLE 143 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 182
TABLE 144 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183
TABLE 145 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 183
TABLE 146 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 147 INDIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 148 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 185
TABLE 149 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 185
12.4.5 REST OF ASIA PACIFIC 185
TABLE 150 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 186
TABLE 151 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
TABLE 152 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 187
TABLE 153 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 154 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 155 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 188
TABLE 156 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 189
12.5 REST OF THE WORLD 189
12.5.1 LATIN AMERICA: RECESSION IMPACT 190
12.5.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 190
TABLE 157 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION) 190
TABLE 158 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191
TABLE 159 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION) 191
TABLE 160 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 192
TABLE 161 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 162 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION) 193
TABLE 163 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 193
13 COMPETITIVE LANDSCAPE 194
13.1 OVERVIEW 194
13.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 194
TABLE 164 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 194
13.3 REVENUE ANALYSIS OF KEY PLAYERS 195
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET 195
13.4 MARKET SHARE ANALYSIS 196
TABLE 165 DEGREE OF COMPETITION: PREIMPLANTATION GENETIC TESTING MARKET 196
13.5 COMPANY EVALUATION MATRIX OF KEY PLAYERS 197
13.5.1 STARS 197
13.5.2 EMERGING LEADERS 197
13.5.3 PERVASIVE PLAYERS 197
13.5.4 PARTICIPANTS 198
FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 198
13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 199
13.6.1 PROGRESSIVE COMPANIES 199
13.6.2 STARTING BLOCKS 199
13.6.3 RESPONSIVE COMPANIES 199
13.6.4 DYNAMIC COMPANIES 199
FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 200
13.7 COMPANY FOOTPRINT ANALYSIS 201
TABLE 166 OVERALL FOOTPRINT 201
TABLE 167 PRODUCT FOOTPRINT 202
TABLE 168 REGIONAL FOOTPRINT 203
13.8 COMPETITIVE BENCHMARKING 204
TABLE 169 DETAILED LIST OF KEY START-UPS/SMES IN PREIMPLANTATION GENETIC TESTING MARKET 204
13.9 COMPETITIVE SCENARIOS AND TRENDS 204
13.9.1 KEY PRODUCT LAUNCHES AND APPROVALS 204
TABLE 170 KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023 204
13.9.2 KEY DEALS 205
TABLE 171 KEY DEALS, 2020–2023 205
13.9.3 OTHER KEY DEVELOPMENTS 205
TABLE 172 OTHER KEY DEVELOPMENTS, 2020–2023 205
14 COMPANY PROFILES 206
14.1 KEY PLAYERS 206
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
14.1.1 ILLUMINA, INC. 206
TABLE 173 ILLUMINA, INC.: COMPANY OVERVIEW 206
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 207
14.1.2 THERMO FISHER SCIENTIFIC INC. 209
TABLE 174 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 209
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 210
14.1.3 AGILENT TECHNOLOGIES, INC. 212
TABLE 175 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 212
FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 213
14.1.4 REVVITY 215
TABLE 176 REVVITY: COMPANY OVERVIEW 215
FIGURE 39 REVVITY: COMPANY SNAPSHOT (2022) 216
14.1.5 THE COOPER COMPANIES, INC. 217
TABLE 177 THE COOPER COMPANIES, INC.: COMPANY OVERVIEW 217
FIGURE 40 THE COOPER COMPANIES INC.: COMPANY SNAPSHOT (2022) 218
14.1.6 ABBOTT 219
TABLE 178 ABBOTT: COMPANY OVERVIEW 219
FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2022) 220
14.1.7 TAKARA BIO INC. 221
TABLE 179 TAKARA BIO INC.: COMPANY OVERVIEW 221
FIGURE 42 TAKARA BIO INC.: COMPANY SNAPSHOT (2022) 222
14.1.8 QIAGEN 223
TABLE 180 QIAGEN.: COMPANY OVERVIEW 223
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2022) 224
14.1.9 VITROLIFE 225
TABLE 181 VITROLIFE.: COMPANY OVERVIEW 225
FIGURE 44 VITROLIFE: COMPANY SNAPSHOT (2022) 226
14.1.10 OXFORD NANOPORE TECHNOLOGIES PLC 228
TABLE 182 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW 228
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
14.2 OTHER PLAYERS 229
14.2.1 OXFORD GENE TECHNOLOGY IP LIMITED 229
14.2.2 YIKON GENOMICS 230
14.2.3 SHIVA SCIENTIFIC COMPANY 230
14.2.4 NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD. 231
14.2.5 MEDICOVER GENETICS 231
14.2.6 MEDGENOME 232
14.2.7 FULGENT GENETICS 232
14.2.8 INVICTA GENETICS 233
14.2.9 GENEA LIMITED 233
14.2.10 SCIEGENE CORPORATION 234
14.2.11 BIOARRAY S.L. 234
14.2.12 UNIMED BIOTECH (SHANGHAI) CO., LTD. 235
14.2.13 GENEMIND BIOSCIENCES CO., LTD. 235
14.2.14 BERRY GENOMICS 236
14.2.15 BANGKOK GENOMICS INNOVATION 236
15 APPENDIX 237
15.1 DISCUSSION GUIDE 237
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
15.3 CUSTOMIZATION OPTIONS 244
15.4 RELATED REPORTS 244
15.5 AUTHOR DETAILS 245